Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy
The adoptive transfer of the chimeric antigen receptor (CAR) expressing T-cells has produced unprecedented successful results in the treatment of B-cell malignancies. However, the use of this technology in other malignancies remains less effective. In the setting of solid neoplasms, CAR T-cell metab...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/1/14 |
| _version_ | 1797543686128533504 |
|---|---|
| author | Marsha Pellegrino Francesca Del Bufalo Biagio De Angelis Concetta Quintarelli Ignazio Caruana Emmanuel de Billy |
| author_facet | Marsha Pellegrino Francesca Del Bufalo Biagio De Angelis Concetta Quintarelli Ignazio Caruana Emmanuel de Billy |
| author_sort | Marsha Pellegrino |
| collection | DOAJ |
| description | The adoptive transfer of the chimeric antigen receptor (CAR) expressing T-cells has produced unprecedented successful results in the treatment of B-cell malignancies. However, the use of this technology in other malignancies remains less effective. In the setting of solid neoplasms, CAR T-cell metabolic fitness needs to be optimal to reach the tumor and execute their cytolytic function in an environment often hostile. It is now well established that both tumor and T cell metabolisms play critical roles in controlling the immune response by conditioning the tumor microenvironment and the fate and activity of the T cells. In this review, after a brief description of the tumoral and T cell metabolic reprogramming, we summarize the latest advances and new strategies that have been developed to improve the metabolic fitness and efficacy of CAR T-cell products. |
| first_indexed | 2024-03-10T13:49:11Z |
| format | Article |
| id | doaj.art-33c7ef71f5374bb682d970fe4adadfdc |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T13:49:11Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-33c7ef71f5374bb682d970fe4adadfdc2023-11-21T02:20:53ZengMDPI AGCells2073-44092020-12-011011410.3390/cells10010014Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell ImmunotherapyMarsha Pellegrino0Francesca Del Bufalo1Biagio De Angelis2Concetta Quintarelli3Ignazio Caruana4Emmanuel de Billy5Department of Onco-hematology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital–IRCCS, 00146 Rome, ItalyDepartment of Onco-hematology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital–IRCCS, 00146 Rome, ItalyDepartment of Onco-hematology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital–IRCCS, 00146 Rome, ItalyDepartment of Onco-hematology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital–IRCCS, 00146 Rome, ItalyDepartment of Onco-hematology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital–IRCCS, 00146 Rome, ItalyDepartment of Onco-hematology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital–IRCCS, 00146 Rome, ItalyThe adoptive transfer of the chimeric antigen receptor (CAR) expressing T-cells has produced unprecedented successful results in the treatment of B-cell malignancies. However, the use of this technology in other malignancies remains less effective. In the setting of solid neoplasms, CAR T-cell metabolic fitness needs to be optimal to reach the tumor and execute their cytolytic function in an environment often hostile. It is now well established that both tumor and T cell metabolisms play critical roles in controlling the immune response by conditioning the tumor microenvironment and the fate and activity of the T cells. In this review, after a brief description of the tumoral and T cell metabolic reprogramming, we summarize the latest advances and new strategies that have been developed to improve the metabolic fitness and efficacy of CAR T-cell products.https://www.mdpi.com/2073-4409/10/1/14cancermetabolic reprogrammingcombined therapyChimeric Antigen Receptor T cellsimmunotherapy |
| spellingShingle | Marsha Pellegrino Francesca Del Bufalo Biagio De Angelis Concetta Quintarelli Ignazio Caruana Emmanuel de Billy Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy Cells cancer metabolic reprogramming combined therapy Chimeric Antigen Receptor T cells immunotherapy |
| title | Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy |
| title_full | Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy |
| title_fullStr | Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy |
| title_full_unstemmed | Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy |
| title_short | Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy |
| title_sort | manipulating the metabolism to improve the efficacy of car t cell immunotherapy |
| topic | cancer metabolic reprogramming combined therapy Chimeric Antigen Receptor T cells immunotherapy |
| url | https://www.mdpi.com/2073-4409/10/1/14 |
| work_keys_str_mv | AT marshapellegrino manipulatingthemetabolismtoimprovetheefficacyofcartcellimmunotherapy AT francescadelbufalo manipulatingthemetabolismtoimprovetheefficacyofcartcellimmunotherapy AT biagiodeangelis manipulatingthemetabolismtoimprovetheefficacyofcartcellimmunotherapy AT concettaquintarelli manipulatingthemetabolismtoimprovetheefficacyofcartcellimmunotherapy AT ignaziocaruana manipulatingthemetabolismtoimprovetheefficacyofcartcellimmunotherapy AT emmanueldebilly manipulatingthemetabolismtoimprovetheefficacyofcartcellimmunotherapy |